Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v5-FR
Language French French
Date Updated 2019-05-24 2019-05-24
Drug Identification Number 02026961 02026961
Brand name KAYEXALATE KAYEXALATE
Common or Proper name Kayexalate Kayexalate
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients SODIUM POLYSTYRENE SULFONATE SODIUM POLYSTYRENE SULFONATE
Strength(s) 100% 100%
Dosage form(s) POWDER POWDER
Route of administration ORAL RECTAL ORAL RECTAL
Packaging size 1 1
ATC code V03AE V03AE
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-04-26 2019-04-26
Actual start date
Estimated end date 2019-08-30 2019-08-30
Actual end date 2019-05-22 2019-05-22
Shortage status Resolved Resolved
Company comments Production delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy Production delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy
Health Canada comments